Advances in Psychiatric Treatment (2008) 14: 3-9. doi: 10.1192/apt.bp.105.000901
© 2008 The Royal College of Psychiatrists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Related articles in APT
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Timimi, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Timimi, S.

Child psychiatry and its relationship with the pharmaceutical industry: theoretical and practical issues{dagger}

Sami Timimi

Sami Timimi is a consultant child and adolescent psychiatrist who works full time in the National Health Service (Child and Adolescent Mental Health Service, Ash Villa, Willoughby Road, South Rauceby, Sleaford, Lincolnshire NG34 8QA, UK. Email: stimimi{at}talk21.com) and a visiting professor of child and adolescent psychiatry at Lincoln University. He writes from a critical perspective on many topics, including eating disorders, psychotherapy, behavioural disorders and cross-cultural psychiatry.

Abstract

The pharmaceutical industry is primarily responsible to its shareholders and so making profit is its primary motivation. The industry’s marketing techniques affect not only prescribing habits of doctors but also concepts of mental health. This editorial examines the impact this has had on both theory and practice in child and adolescent psychiatry. Undue influence by the pharmaceutical industry contributes to a skewing of the literature towards biological disease models of childhood mental health in order to support the use of the pharmaceutical companies’ products. Using fluoxetine and stimulants as two case examples, the article illustrates how pharmaceutical companies have contributed to widespread acceptance of erroneous beliefs about the safety and efficacy of using psychotropic drugs in children and adolescents. Suggestions are made on how child psychiatrists, both individually and collectively, can incorporate this knowledge into their professional development and practice.


Related articles in APT:

Pharmacotherapy and child psychiatry: is there a way forward?: INVITED COMMENTARY ON... CHILD PSYCHIATRY AND ITS RELATIONSHIP WITH THE PHARMACEUTICAL INDUSTRY
A. James
APT 2008 14: 10-16. [Abstract] [Full Text]  



This article has been cited by other articles:


Home page
 Psychiatr. Bull.Home page
E. E. Hare
E-learning for psychiatrists
Psychiatr. Bull., March 1, 2009; 33(3): 81 - 83.
[Abstract] [Full Text] [PDF]

eLetters:

Read all eLetters

Pharmaceutical industry and its influence on Child Psychiatry
Imran Mushtaq, et al.
Advances Online, 3 Mar 2008 [Full text]